Assessment of Geriatric Evaluations Impact on New AML Guidance

Recruiting Observational Study
AML, Adult
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
50 and older
Sex
Any
Study type
Observational
Participants needed
100 (estimated)
Sponsor
Abramson Cancer Center at Penn Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term su…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy * New diagnosis being considered for new line of treatment * Age ≥ 50 years. * Performance status 0,1, and 2 Exclusion Criteria: * Inability to understand or unable to sign a written informed c…
Contacts

Colleen Redlinger

2152209693

colleen.redlinger@pennmedicine.upenn.edu

CONTACT

Catherine Lai, MD

2153600561

Catherine.Lai@Pennmedicine.upenn.edu

CONTACT